肝脏 ›› 2026, Vol. 31 ›› Issue (9): 1258-1262.

• 病毒性肝炎 • 上一篇    下一篇

血液透析患者合并丙型肝炎抗病毒治疗的临床特征

刘海燕, 赵娜新, 任雯雯, 刘晓莉, 曾志立, 郭贺冰, 向攀   

  1. 100015 北京 首都医科大学附属北京地坛医院肾内科 (刘海燕,赵娜新,任雯雯,刘晓莉,曾志立,向攀),重症医学科(郭贺冰)
  • 收稿日期:2025-09-04 出版日期:2026-09-30 发布日期:2026-11-16

The clinical characteristics of hemodialysis combined with antiviral therapy in hepatitis C patients

Liu Haiyan1, Zhao Naxin1, Ren Wenwen1, Liu Xiaoli1, Zeng Zhili1, Guo Hebing2, Xiang pan1   

  1. 1. Department of Nephrology, Beijing Ditan Hospital,Capital Medical University, Beijing 100015, China;
    2. Department of Intensive Care Medicine,Beijing Ditan Hospital,Capital Medical University, Beijing 100015, China
  • Received:2025-09-04 Online:2026-09-30 Published:2026-11-16

摘要: 目的 分析血液透析患者合并丙型肝炎抗病毒治疗的临床特征。方法 回顾性分析2022年1月至2023年3月在首都医科大学附属北京地坛医院肾内科血液净化中心常规血液透析合并丙型肝炎抗病毒治疗患者(5例)的临床资料及诊疗方法。结果 5例患者中,慢性肾小球肾炎2例,缺血性肾病合并糖尿病肾病1例,神经源性膀胱1例,1例糖尿病肾病可能性大。所有患者均有输血史,部分患者进行了基因型检测,其中1例为1b型,1例未分型成功,其余未见化验报告单;抗病毒治疗前行病毒载量(HCV RNA)检测,5例患者均大于105 IU/mL。其中3例应用索磷布韦维帕他韦抗病毒治疗,1例先后应用干扰素及索磷布韦维帕他韦抗抗病毒治疗,1例应用艾尔巴韦格拉瑞韦进行抗丙型肝炎病毒治疗。5例患者中,4例为慢性丙型肝炎,1例为失代偿期肝硬化,5例均为早期应答。5例患者经抗病毒治疗后,HCV RNA均已转阴,且服用直接抗病毒药物后均未出现不良反应。结论 直接抗病毒治疗在重度肾功能不全、血液透析患者中安全有效,对肾功能无不良影响。

关键词: 慢性肾脏病, 血液透析, 丙型肝炎, 索磷布韦维帕他韦, 艾尔巴韦格拉瑞韦

Abstract: Objective To analyze the clinical characteristics of patients undergoing hemodialysis who received antiviral therapy for hepatitis C viral (HCV) infection. Methods Performed a retrospective analysis on the clinical data and treatment methods of five patients with HCV infection who underwent routine hemodialysis and received antiviral therapy between January 2022 and March 2023 at the blood purification center of Beijing Ditan Hospital affiliated to Capital Medical University. Results Among the 5 patients, two had chronic glomerulonephritis, one had ischemic nephropathy combined with diabetic nephropathy, one had neurogenic bladder, and one was highly possible to have diabetic nephropathy. All patients had a history of blood transfusion. Some patients underwent HCV genotype testing. Among them, one case was genotype 1b, one case was not successfully typed, and no laboratory test reports were found for the rest of patients. Before antiviral treatment, the viral load (HCV RNA) was detected. All 5 patients had a viral load greater than 105 IU/mL. Among them, three patients received sofosbuvir-velpatasvir antiviral therapy, one patient received interferon and sofosbuvir-velpatasvir antiviral therapy sequentially, and one patient received elbasvir-grazoprevir antiviral therapy against HCV. Among the 5 patients, four had chronic hepatitis C, one had decompensated cirrhosis. All of them obtained an early response. After antiviral therapy, sustained virological response was achieved in all five patients, and no adverse reactions occurred after taking the direct-acting antiviral drugs. Conclusion Direct-acting antiviral therapy is safe and effective in patients with severe renal insufficiency undergoing hemodialysis, and has no adverse effects on renal function.

Key words: Chronic kidney disease, Hemodialysis, Hepatitis C, Sofosbuvir-velpatasvir, Elbasvir-grazoprevir